Minerva Neurosciences, Inc. (NERV) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low34.8·High34.8
P/FCF
N/A
—
5yr avg: N/A
30Y Low75.5·High75.5
P/B Ratio
N/A
—
5yr avg: 4.29
30Y Low1.7·High10.0
ROE
N/A
—
5yr avg: -164.6%
30Y Low-165%·High5%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.1·High0.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NERV Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Minerva Neurosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $32M | $34M | $17M | $40M | $8M | $34M | $96M | $277M | $261M | $230M | $370M |
| Enterprise Value | $14M | $17M | $-4547728 | $-900675 | $-27603006 | $-26525680 | $71M | $256M | $211M | $207M | $296M |
| P/E Ratio → | -0.13 | — | 11.68 | — | — | — | 49.26 | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | 2.33 | — | — | — | — |
| P/B Ratio | — | — | — | — | — | 4.29 | 1.82 | 9.99 | 2.90 | 1.74 | 3.49 |
| P/FCF | — | — | — | — | — | — | — | — | — | 75.49 | — |
| P/OCF | — | — | — | — | — | — | — | — | — | 74.21 | — |
P/E links to full P/E history page with 30-year chart
NERV EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | 1.71 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | 34.85 | — | — | — | — |
| EV / EBIT | — | — | -0.76 | — | — | — | 36.33 | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | 68.22 | — |
NERV Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | 100.0% | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | 4.5% | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | 4.7% | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | -164.6% | 4.8% | -122.3% | -45.2% | -26.5% | -38.5% |
| ROA | -434.3% | -434.3% | 3.1% | -53.6% | -48.6% | -74.1% | 2.9% | -66.6% | -31.1% | -19.9% | -28.8% |
| ROIC | — | — | — | — | — | — | 8.1% | -243.8% | -51.9% | -43.7% | -54.8% |
| ROCE | -23.2% | -23.2% | -49.7% | -43.1% | -39.4% | -70.5% | 2.9% | -73.5% | -33.1% | -27.4% | -30.1% |
NERV Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $82M exceeds total debt of $65M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.00 | 0.01 | — | 0.03 | 0.08 |
| Debt / EBITDA | — | — | — | — | — | — | 0.05 | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | -7.62 | -0.48 | -0.76 | -0.56 | -0.17 | -0.70 |
| Net Debt / EBITDA | — | — | — | — | — | — | -12.48 | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | -7.27 | — |
| Interest Coverage | — | — | 1.32 | -2.62 | -3.33 | -7.17 | — | — | -453.25 | -65.58 | -29.14 |
Net cash position: cash ($82M) exceeds total debt ($65M)
NERV Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Minerva Neurosciences, Inc.'s current ratio of 36.29x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 12.57x to 36.29x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 36.29 | 36.29 | 7.85 | 12.57 | 29.15 | 22.07 | 8.68 | 7.11 | 24.94 | 18.94 | 8.66 |
| Quick Ratio | 36.29 | 36.29 | 7.85 | 12.57 | 29.15 | 22.07 | 8.68 | 7.11 | 24.94 | 18.94 | 8.66 |
| Cash Ratio | 35.94 | 35.94 | 7.53 | 12.25 | 26.20 | 21.55 | 8.02 | 6.92 | 24.38 | 18.74 | 8.57 |
| Asset Turnover | — | — | — | — | — | — | 0.71 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
NERV Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Minerva Neurosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 8.6% | — | — | — | 2.0% | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | 1.3% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $8M | $8M | $7M | $5M | $5M | $5M | $5M | $5M | $5M | $4M |
Peer Comparison
Compare NERV with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NERVYou | $32M | -0.1 | — | — | — | — | — | — | — |
 ACAD | $4B | 9.2 | 25.1 | 34.3 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 6.8 | 8.6 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 AXSM | $13B | -69.3 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 ALTO | $441M | 35.6 | 15.6 | 50.9 | 3.8% | 0.8% | 5.7% | 1.9% | 3.0 |
 NRXP | $66M | -2.9 | — | — | 58.8% | -1324.4% | — | — | — |
 PRAX | $8B | -19.8 | — | — | — | — | -45.8% | -65.0% | — |
 PTCT | $6B | 9.7 | 6.4 | 8.9 | 95.9% | 49.5% | — | — | 0.5 |
 SNDX | $2B | -5.5 | — | — | 96.0% | -158.4% | -161.8% | -54.2% | — |
 LLY | $1.1T | 49.4 | 35.4 | 119.3 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 JNJ | $580B | 41.6 | 20.1 | 29.3 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
What if you invested $1,000 in NERV 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in NERV be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs NERV Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationNERV vs ACAD — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs ACADIA Pharmaceuticals Inc..
Compare NowNERV — Frequently Asked Questions
Quick answers to the most common questions about buying NERV stock.
What is Minerva Neurosciences, Inc.'s P/E ratio?
Minerva Neurosciences, Inc.'s current P/E ratio is -0.1x. The historical average is 30.5x.
Is NERV stock overvalued?
Based on historical data, Minerva Neurosciences, Inc. is trading at a P/E of -0.1x. Compare with industry peers and growth rates for a complete picture.